FDA APPROVALS
Hepatitis C pricing heats up with ...

Much of the drug pricing debate in the United States in recent months has centered around the soaring prices of hepatitis ...

FDA clears long-acting ADHD drug
FDA expands Opdivo use for ...
J&J’s antibiotic faces $800M lawsuit

CLINICAL
Hepatitis C pricing heats up with ...

Much of the drug pricing debate in the United States in recent months has centered around the soaring prices of hepatitis ...

FDA clears long-acting ADHD drug
FDA expands Opdivo use for ...
J&J’s antibiotic faces $800M lawsuit

DRUGS IN PERSPECTIVE
Drugs in Perspective: Opdivo (nivolumab)

On December 22, 2014, Opdivo (nivolumab) was approved by FDA with a breakthrough therapy designation. Nivolumab is the ...

Poll

View Results